-
Talimogene laherparepvec, sold
under the
brand name
Imlygic among others, is a
biopharmaceutical medication used to
treat melanoma that
cannot be operated...
- in
China in 2005 for the
treatment of head and neck cancer. In 2015,
talimogene laherparepvec (OncoVex, T-VEC), an
oncolytic herpes virus which is a modified...
-
notable variants—those
tested in
clinical trials: G207, HSV1716, NV1020 and
Talimogene laherparepvec (previously Oncovex-GMCSF).
These attenuated versions are...
- virotherapy,
commercialized by
Amgen Inc. This
oncolytic herpes virus,
named Talimogene laherparepvec, has been
genetically engineered to
express human GM-CSF...
- the
patient using oncolytic viruses. This
approach was used in the drug
talimogene laherparepvec, a
variant of
herpes simplex virus engineered to selectively...
-
reproduce in
cancer cells and
destroy them but not
infect healthy cells.
Talimogene laherparepvec (T-VEC), for example, is a
modified herpes simplex virus...
-
makes use of
Mycobacterium bovis strain for
bladder invasive cancer.
Talimogene laherparepvec (T-VEC or Imlygic) is a
vaccine for
advanced oncolytic melanoma...
- 2 Strimvelis:
treatment for
adenosine deaminase deficiency (ADA-SCID)
Talimogene laherparepvec (Imlygic):
treatment for
melanoma in
people who have recurring...
-
increase metabolism,
reduce anti-tumor
immunity and
disorganize vasculature.
Talimogene laherparepvec (T-VEC) (which is a
herpes simplex virus type 1–derived...
-
prostate cancer. 2011: In May,
Amgen acquired BioVex,
developer of
Imlygic (
talimogene laherparepvec). In December,
Amgen and
Watson Pharmaceuticals announced...
